Sports Medicine has published a narrative review of approved and unapproved peptides marketed direct to patients, covering AOD-9604, BPC-157, CJC-1295, follistatin-344, GHK-Cu, ipamorelin, MOTS-c, sermorelin, SS-31 (elamipretide), tesamorelin, thymosin beta-4 and its TB-500 fragment. Ten of those are lines in this catalogue.
The authors are blunt about where things stand: many of these peptides show favourable tissue repair or metabolic outcomes in animal models, rigorous human safety data are scarce, and a parallel market has grown up largely outside regulatory oversight with real potential for harm. We agree with all three parts of that. It is why the range is sold business-to-business to verified research organisations only, why every carton and vial carries a Research Use Only statement, and why we publish no protocols for administration.
One of them now has an approved reference product
Elamipretide — SS-31, listed here as NMR-17 — was approved by the FDA on 19 September 2025 as Forzinity, to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. That makes it one of the few molecules in this range with an approved product behind it. It does not make our material a medicine. What leaves Norman is a reagent, and the label says so.
Sources: Mendias CL and Awan TM, Sports Medicine, August 2026 (PubMed 41966639); FDA, Novel Drug Approvals for 2025.